Withdrawals due to adverse events · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher tolerability (withdrawal due to adverse events) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
Mirtazapine showed no clear difference in tolerability: withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with cervical dystonia
Botulinum neurotoxin B showed no clear difference in proportion of withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in withdrawals due to adverse events during longest compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · hyperuricaemia in people with hypertension
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with ankylosing spondylitis
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse outcomes · atopic eczema
1 finding from 1 review
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review